FRA10AC1: A Drug Target / Disease Biomarker (G118924)

Target Name: FRA10AC1

NCBI ID: G118924

FRA10AC1

FRA10AC1: A Drug Target / Disease Biomarker

FRA10AC1 is a protein that is expressed in the human placenta and has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is derived from the FRA1 gene, which encodes a protein known as FRA1, which is a key regulator of cell growth and differentiation.

FRA10AC1 is a 19kDa protein that is expressed in the placenta, liver, and other tissues of the body. It is characterized by a N-terminus that is similar to that of the FRA1 gene, but with a unique extension that is unique to FRA10AC1. FRA10AC1 is also known as FRA100, and it is a single gene that encodes a protein that is expressed in various tissues of the body.

One of the key functions of FRA10AC1 is its role in cell growth and differentiation. The protein is involved in the regulation of cell proliferation, and it has been shown to play a role in the development and progression of various diseases, including cancer.

FRA10AC1 has also been shown to be involved in the regulation of cell migration and adhesion. The protein is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent the movement of harmful substances into the body.

In addition to its role in cell growth and differentiation, FRA10AC1 has also been shown to be involved in the regulation of cellular signaling pathways. The protein is involved in the regulation of the PI3K/Akt signaling pathway, which is a key pathway that is involved in the regulation of cellular signaling pathways that are involved in cell growth, differentiation, and survival.

FRA10AC1 is also a potential biomarker for various diseases, including cancer. The protein has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that FRA10AC1 is involved in the regulation of cellular signaling pathways that are involved in cancer growth and progression, which could make it an attractive target for cancer therapies.

In conclusion, FRA10AC1 is a protein that is expressed in the placenta and has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is involved in the regulation of cell growth and differentiation, as well as cell migration and adhesion, and it is also involved in the regulation of cellular signaling pathways that are involved in cancer growth and progression. Further research is needed to determine the full role of FRA10AC1 in these processes and to develop effective therapies for cancer.

Protein Name: FRA10A Associated CGG Repeat 1

Functions: May be involved in pre-mRNA splicing

The "FRA10AC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRA10AC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets